Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models.

Thomas SM, Sahu B, Rapireddy S, Bahal R, Wheeler SE, Procopio EM, Kim J, Joyce SC, Contrucci S, Wang Y, Chiosea SI, Lathrop KL, Watkins S, Grandis JR, Armitage BA, Ly DH.

ACS Chem Biol. 2013 Feb 15;8(2):345-52. doi: 10.1021/cb3003946. Epub 2012 Nov 9.

2.

Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.

Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.

Cell Death Dis. 2015 Aug 6;6:e1850. doi: 10.1038/cddis.2015.217.

3.

Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.

Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC.

Mol Pharmacol. 2008 Mar;73(3):627-38. Epub 2007 Nov 19.

4.

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.

Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR.

Cancer Biol Ther. 2012 Aug;13(10):935-45. doi: 10.4161/cbt.20846. Epub 2012 Aug 1.

5.
6.

AXL mediates resistance to cetuximab therapy.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL.

Cancer Res. 2014 Sep 15;74(18):5152-64. doi: 10.1158/0008-5472.CAN-14-0294. Epub 2014 Aug 18.

7.

Cell-permeable peptide nucleic acid designed to bind to the 5'-untranslated region of E-cadherin transcript induces potent and sequence-specific antisense effects.

Dragulescu-Andrasi A, Rapireddy S, He G, Bhattacharya B, Hyldig-Nielsen JJ, Zon G, Ly DH.

J Am Chem Soc. 2006 Dec 20;128(50):16104-12.

PMID:
17165763
8.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

9.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

10.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

11.

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM.

Cancer Res. 2013 Jan 15;73(2):824-33. doi: 10.1158/0008-5472.CAN-12-1611. Epub 2012 Nov 20.

12.
13.

Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR.

Neoplasia. 2012 Nov;14(11):1005-14.

14.

Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.

PLoS One. 2011;6(8):e23756. doi: 10.1371/journal.pone.0023756. Epub 2011 Aug 17.

15.

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.

Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM.

Mol Cancer Ther. 2015 May;14(5):1141-51. doi: 10.1158/1535-7163.MCT-14-0820. Epub 2015 Mar 2.

16.

Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.

Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ.

Clin Cancer Res. 2007 Mar 1;13(5):1540-51.

17.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

18.

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.

Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA.

Clin Cancer Res. 2008 Nov 1;14(21):6963-73. doi: 10.1158/1078-0432.CCR-08-0957.

20.

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.

PLoS One. 2016 Mar 10;11(3):e0150567. doi: 10.1371/journal.pone.0150567. eCollection 2016.

Supplemental Content

Support Center